Inhaled protein could train lungs to fight pneumonia

NCT ID NCT06681402

Completed Disease control Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a single inhaled dose of FLAMOD, a protein that mimics a bacterial signal to activate the immune system, in 46 healthy adults. The goal was to check safety and see if it triggers a local immune response in the lungs. If it works, this approach might one day help prevent pneumonia in vulnerable people.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FLAMOD (a lab-made protein that mimics bacterial flagellin to activate the immune system)
What this could lead to: If successful, this could lead to a new way to boost lung immunity and prevent pneumonia in at-risk people.
What could go wrong: This is an early Phase I safety trial in only 46 healthy volunteers, so it cannot yet prove the drug works against pneumonia. Side effects or lack of immune activation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumonia Respiratory Aspiration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMONIA

Contacts and locations

Locations

Centre hospitalier régional universitaire de de Tours

Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.